{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.210","value":"0.74"},{"groupId":"OG001","spread":"0.181","value":"0.76"},{"groupId":"OG002","spread":"0.222","value":"0.73"},{"groupId":"OG003","spread":"0.219","value":"0.75"},{"groupId":"OG004","spread":"0.244","value":"0.73"},{"groupId":"OG005","spread":"0.203","value":"0.75"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"167"},{"groupId":"OG001","value":"181"},{"groupId":"OG002","value":"161"},{"groupId":"OG003","value":"235"},{"groupId":"OG004","value":"83"},{"groupId":"OG005","value":"264"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.194","value":"0.05"},{"groupId":"OG001","spread":"0.199","value":"-0.10"},{"groupId":"OG002","spread":"0.196","value":"0.00"},{"groupId":"OG003","spread":"0.204","value":"0.06"},{"groupId":"OG004","spread":"0.246","value":"-0.06"},{"groupId":"OG005","spread":"0.214","value":"-0.09"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"153"},{"groupId":"OG001","value":"157"},{"groupId":"OG002","value":"143"},{"groupId":"OG003","value":"224"},{"groupId":"OG004","value":"67"},{"groupId":"OG005","value":"224"}],"units":"Participants"}],"title":"Change at Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.196","value":"0.04"},{"groupId":"OG001","spread":"0.220","value":"-0.15"},{"groupId":"OG002","spread":"0.196","value":"-0.04"},{"groupId":"OG003","spread":"0.218","value":"0.07"},{"groupId":"OG004","spread":"0.231","value":"-0.06"},{"groupId":"OG005","spread":"0.227","value":"-0.13"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"136"},{"groupId":"OG001","value":"139"},{"groupId":"OG002","value":"116"},{"groupId":"OG003","value":"206"},{"groupId":"OG004","value":"59"},{"groupId":"OG005","value":"198"}],"units":"Participants"}],"title":"Change at Cycle 5 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.201","value":"0.05"},{"groupId":"OG001","spread":"0.189","value":"-0.13"},{"groupId":"OG002","spread":"0.215","value":"-0.03"},{"groupId":"OG003","spread":"0.237","value":"0.06"},{"groupId":"OG004","spread":"0.220","value":"-0.16"},{"groupId":"OG005","spread":"0.199","value":"-0.14"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"125"},{"groupId":"OG001","value":"116"},{"groupId":"OG002","value":"88"},{"groupId":"OG003","value":"187"},{"groupId":"OG004","value":"53"},{"groupId":"OG005","value":"169"}],"units":"Participants"}],"title":"Change at Cycle 7 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.237","value":"0.03"},{"groupId":"OG001","spread":"0.197","value":"-0.15"},{"groupId":"OG002","spread":"0.237","value":"-0.04"},{"groupId":"OG003","spread":"0.192","value":"0.07"},{"groupId":"OG004","spread":"0.202","value":"-0.11"},{"groupId":"OG005","spread":"0.199","value":"-0.14"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"114"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"68"},{"groupId":"OG003","value":"163"},{"groupId":"OG004","value":"43"},{"groupId":"OG005","value":"130"}],"units":"Participants"}],"title":"Change at Cycle 9 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.197","value":"0.04"},{"groupId":"OG001","spread":"0.206","value":"-0.18"},{"groupId":"OG002","spread":"0.238","value":"-0.01"},{"groupId":"OG003","spread":"0.195","value":"0.06"},{"groupId":"OG004","spread":"0.230","value":"-0.16"},{"groupId":"OG005","spread":"0.213","value":"-0.17"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"95"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"144"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"105"}],"units":"Participants"}],"title":"Change at Cycle 11 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.225","value":"0.05"},{"groupId":"OG001","spread":"0.206","value":"-0.17"},{"groupId":"OG002","spread":"0.263","value":"-0.02"},{"groupId":"OG003","spread":"0.254","value":"0.05"},{"groupId":"OG004","spread":"0.216","value":"-0.20"},{"groupId":"OG005","spread":"0.208","value":"-0.18"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"63"},{"groupId":"OG002","value":"40"},{"groupId":"OG003","value":"130"},{"groupId":"OG004","value":"27"},{"groupId":"OG005","value":"90"}],"units":"Participants"}],"title":"Change at Cycle 13 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.208","value":"0.05"},{"groupId":"OG001","spread":"0.203","value":"-0.18"},{"groupId":"OG002","spread":"0.280","value":"-0.07"},{"groupId":"OG003","spread":"0.259","value":"0.05"},{"groupId":"OG004","spread":"0.262","value":"-0.26"},{"groupId":"OG005","spread":"0.218","value":"-0.20"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"61"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"101"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"78"}],"units":"Participants"}],"title":"Change at Cycle 15 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.193","value":"0.07"},{"groupId":"OG001","spread":"0.165","value":"-0.14"},{"groupId":"OG002","spread":"0.173","value":"-0.02"},{"groupId":"OG003","spread":"0.188","value":"0.06"},{"groupId":"OG004","spread":"0.332","value":"-0.20"},{"groupId":"OG005","spread":"0.203","value":"-0.15"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"56"},{"groupId":"OG002","value":"25"},{"groupId":"OG003","value":"66"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"68"}],"units":"Participants"}],"title":"Change at Cycle 17 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.239","value":"0.03"},{"groupId":"OG001","spread":"0.235","value":"-0.18"},{"groupId":"OG002","spread":"0.214","value":"-0.02"},{"groupId":"OG003","spread":"0.231","value":"0.05"},{"groupId":"OG004","spread":"0.328","value":"-0.11"},{"groupId":"OG005","spread":"0.249","value":"-0.17"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"51"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"28"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"60"}],"units":"Participants"}],"title":"Change at Cycle 19 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.132","value":"0.07"},{"groupId":"OG001","spread":"0.198","value":"-0.14"},{"groupId":"OG002","spread":"0.159","value":"-0.04"},{"groupId":"OG003","spread":"0.174","value":"0.12"},{"groupId":"OG004","value":"-0.11"},{"groupId":"OG005","spread":"0.196","value":"-0.14"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"42"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"43"}],"units":"Participants"}],"title":"Change at Cycle 21 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.139","value":"0.04"},{"groupId":"OG001","spread":"0.147","value":"-0.11"},{"groupId":"OG002","spread":"0.171","value":"-0.05"},{"groupId":"OG005","spread":"0.147","value":"-0.11"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"33"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"33"}],"units":"Participants"}],"title":"Change at Cycle 23 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.135","value":"0.07"},{"groupId":"OG001","spread":"0.207","value":"-0.11"},{"groupId":"OG002","spread":"0.221","value":"-0.17"},{"groupId":"OG005","spread":"0.207","value":"-0.11"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"26"}],"units":"Participants"}],"title":"Change at Cycle 25 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.081","value":"0.03"},{"groupId":"OG001","spread":"0.347","value":"-0.09"},{"groupId":"OG002","spread":"0.103","value":"-0.14"},{"groupId":"OG003","spread":"0.481","value":"-0.27"},{"groupId":"OG004","spread":"0.061","value":"-0.06"},{"groupId":"OG005","spread":"0.249","value":"-0.08"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"9"}],"units":"Participants"}],"title":"Change at End of treatment visit"}],"denoms":[{"counts":[{"groupId":"OG000","value":"167"},{"groupId":"OG001","value":"181"},{"groupId":"OG002","value":"161"},{"groupId":"OG003","value":"235"},{"groupId":"OG004","value":"83"},{"groupId":"OG005","value":"264"}],"units":"Participants"}],"description":"EQ-5D-5L is a standardized participant completed questionnaire that measures health status in terms of a single index value or utility score. EQ-5D-5L consisted of two components: a health state profile (descriptive system) and a visual analogue scale (VAS) in which participants rate their overall health status from 0 (worst imaginable) to 100 (best imaginable), where higher scores indicated better health status. EQ-5D health state profile is comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 response levels: 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. EQ-5D-5L health status index score range between 0 to 1. Higher score indicated better health status.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received 450 milligram (mg) of LGX818 orally once daily (QD) along with 45 mg of MEK162 twice daily (BID) for each 28 day treatment cycle until progressive disease (PD) as confirmed by Blinded Independent Review Committee (BIRC), withdrawal of consent, intolerable toxicity, study discontinuation, lost to follow-up or death.","id":"OG000","title":"Part 1:LGX818 450 mg QD+MEK162 45 mg BID (Combo 450)"},{"description":"Participants received 300 mg of LGX818 orally once daily for each 28 day treatment cycle until PD as confirmed by BIRC, withdrawal of consent, intolerable toxicity, study discontinuation, lost to follow-up or death.","id":"OG001","title":"Part 1: LGX818 300 mg"},{"description":"Participants received 960 mg of Vemurafenib according to the locally approved prescribing information twice daily for each 28 day treatment cycle until PD as confirmed by BIRC, withdrawal of consent, intolerable toxicity, study discontinuation, lost to follow-up or death.","id":"OG002","title":"Part 1: Vemurafenib 960 mg BID"},{"description":"Participants received 300 mg of LGX818 orally once daily along with 45 mg of MEK162 twice daily for each 28 day treatment cycle until PD as confirmed by BIRC, withdrawal of consent, intolerable toxicity, study discontinuation, lost to follow-up or death.","id":"OG003","title":"Part 2: LGX818 300 mg QD+MEK162 45 mg BID (Combo 300)"},{"description":"Participants received 300 mg of LGX818 orally once daily for each 28 day treatment cycle until PD as confirmed by BIRC, withdrawal of consent, intolerable toxicity, study discontinuation, lost to follow-up or death.","id":"OG004","title":"Part 2: LGX818 300 mg"},{"description":"Participants of Part 1 and 2 received 300 mg of LGX818 orally once daily for each 28 day treatment cycle until PD as confirmed by BIRC, withdrawal of consent, intolerable toxicity, and study discontinuation, lost to follow-up or death.","id":"OG005","title":"Part 1 + Part 2: LGX818 300 mg"}],"paramType":"MEAN","populationDescription":"FAS included all randomized participants. Here, \"Overall Number of Participants Analyzed\" signifies number of participants evaluable for this outcome measure and \"Number analyzed\" signifies participants evaluable for each specified row. It was planned to report combined result data of Part 1 and Part 2 for LGX818 300 mg arm.","reportingStatus":"POSTED","timeFrame":"Baseline (Day 1 of Cycle 1), Day 1 of Cycle 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 and end of treatment visit (within14 days after the last dose of study drug)","title":"Part 1 and Part 2: Change From Baseline in EuroQoL-5 Dimension-5 Level (EQ-5D-5L) Index Score at Day 1 of Cycle 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 and End of Treatment Visit","type":"SECONDARY","unitOfMeasure":"Units on a scale"}